175 related articles for article (PubMed ID: 37422014)
1. Treatment response and tolerability of intralesional quadrivalent versus bivalent human papillomavirus vaccine for recalcitrant warts: A randomized controlled trial.
Nofal A; Nofal H; Alwirshiffani E; ElGhareeb MI
J Am Acad Dermatol; 2023 Nov; 89(5):1051-1052. PubMed ID: 37422014
[No Abstract] [Full Text] [Related]
2. Intralesional bivalent and quadrivalent human papillomavirus vaccines didn't significantly enhance the response of multiple anogenital warts when co-administered with intralesional Candida antigen immunotherapy. A randomized controlled trial.
Fawzy M; Nofal E; Abdelkhalek N; Ehab R
Arch Dermatol Res; 2023 Dec; 315(10):2813-2823. PubMed ID: 37573268
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
4. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson R; Nugent D; Bennett K; Doré CJ; Murray ML; Meadows J; Haddow LJ; Lacey C; Sandmann F; Jit M; Soldan K; Tetlow M; Caverly E; Nathan M; Copas AJ
Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
7. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
9. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
McCormack PL
Drugs; 2014 Jul; 74(11):1253-83. PubMed ID: 25022951
[TBL] [Abstract][Full Text] [Related]
10. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
Capri S; Gasparini R; Panatto D; Demarteau N
Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
[TBL] [Abstract][Full Text] [Related]
11. Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts.
Nofal A; Marei A; Ibrahim AM; Nofal E; Nabil M
J Am Acad Dermatol; 2020 Jan; 82(1):94-100. PubMed ID: 31369771
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review.
Gonçalves AK; Cobucci RN; Rodrigues HM; de Melo AG; Giraldo PC
Braz J Infect Dis; 2014; 18(6):651-9. PubMed ID: 24780368
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years.
Yoshikawa H; Ebihara K; Tanaka Y; Noda K
Cancer Sci; 2013 Apr; 104(4):465-72. PubMed ID: 23331518
[TBL] [Abstract][Full Text] [Related]
14. Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts.
Bar-Ilan E; Bar J; Baniel A; Slodownik D; Artzi O; Samuelov L; Sprecher E; Mashiah J
J Dermatol; 2023 Nov; 50(11):1373-1380. PubMed ID: 37501372
[TBL] [Abstract][Full Text] [Related]
15. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
Shu Y; Yu Y; Ji Y; Zhang L; Li Y; Qin H; Huang Z; Ou Z; Huang M; Shen Q; Li Z; Hu M; Li C; Zhang G; Zhang J
Vaccine; 2022 Nov; 40(48):6947-6955. PubMed ID: 36283897
[TBL] [Abstract][Full Text] [Related]
17. Currently approved prophylactic HPV vaccines.
Harper DM
Expert Rev Vaccines; 2009 Dec; 8(12):1663-79. PubMed ID: 19943762
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
[TBL] [Abstract][Full Text] [Related]
19. [Research progress on the differences between T and B cell responses to three different forms of human papilloma virus (HPV) vaccination].
Peng Q; Li Y; Li J; Yao X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Apr; 40(4):378-382. PubMed ID: 38710522
[TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
